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BRCA2
BRCA2 was the second breast cancer susceptibility gene
to be discovered, and was isolated through positional
cloning using data from families with inherited breast
cancer [4]. Cells with mutant BRCA2 protein are, like many
cancer cells, genetically unstable and accumulate gross
chromosomal rearrangements [5,6]. The sequence of this
large protein (3418 amino acids) offers very little clue to its
function, although there are eight repeated segments
(termed BRC repeats) in the middle of the protein that are
highly conserved among mammalian orthologs [7,8].
Breast cancer susceptibility genes and DNA
repair
Following the landmark discovery by Scully et al that the
homologous recombinase RAD51 colocalizes at subnu-
clear sites with BRCA1 [9], a number of additional results
have provided evidence that both BRCA1 and BRCA2 are
involved in recombinational repair of DNA damage.
BRCA1 and BRCA2 form discrete nuclear foci during the
S phase and after exposure to DNA damaging agents
[9–11]. These foci are probably sites of repair of sponta-
neous and induced DNA damage [12–14]. Cell lines
defective in either BRCA1 or BRCA2 are sensitive to
damaging agents that form double-strand breaks (DSBs),
as are other cell lines defective in recombinational repair
(reviewed in [15]). BRCA2 interacts with the RAD51
recombinase via direct protein–protein contacts [16–19].
Biochemical analysis also showed interaction between
BRCA1 and RAD51, although these detected interactions
may have been indirect [9]. The BRC repeats of BRCA2
are responsible for direct RAD51 interaction. Cells lacking
BRCA1/2 fail to form damage-induced subnuclear RAD51
foci with normal efficiency, suggesting that these proteins
are required for the formation of recombinase complexes
at the sites of DNA damage [20,21]. Finally, genetic mea-
surements of recombination frequency have shown that
Brca1–/– embryonic stem (ES) cells are deficient in recom-
binational DSB repair [22,23]. The similarity between phe-
notypes associated with BRCA1 and BRCA2 deficiency,
together with data showing a similar effect of DNA
damage on distribution of BRCA1 and BRCA2 in repair-
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Abstract
Two recent papers provide new evidence relevant to the role of the breast cancer susceptibility gene
BRCA2 in DNA repair. Moynahan et al provide genetic data indicating a requirement for BRCA2 in
homology-dependent (recombinational) repair of DNA double-strand breaks. The second paper, by
Davies  et al, begins to address the mechanism through which BRCA2 makes its contribution to
recombinational repair. BRCA2 appears to function in recombination via interactions with the major
eukaryotic recombinase RAD51 [1–3]. We briefly review the context in which the two studies were
carried out, we comment on the results presented, and we discuss models designed to account for the
role of BRCA2 in RAD51-mediated repair.
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proficient cells, led to the hypothesis that BRCA2, like
BRCA1, is required for efficient recombinational repair.
The paper by Moynahan et al [24] provides important
support for this hypothesis.
Measuring DSB-induced recombination
frequency in BRCA2-defective cells
Pierce et al have designed a set of recombination sub-
strates for measuring the level of homologous recombina-
tion in vivo (Fig. 1) [25]. The DNA substrate contains a
pair of mutated GFP genes (GFP encodes the easily
detected green fluorescent protein), one of which con-
tains a restriction site for I-SceI, a yeast intron encoded
endonuclease with an 18 base pair recognition site. Tran-
sient transfection of an I-SceI expression vector results in
the production of a DSB in the first mutated copy of GFP.
One or both DNA ends formed by the break invade(s) the
homologous sequence in the second mutant GFP copy,
resulting in repair of the DSB via a homology-mediated
gene conversion event. The configuration of the GFP con-
struct is such that homology-mediated repair often results
in the formation of a functional copy of GFP. Such events
can be detected by fluorescence-activated cell sorting
analysis by virtue of their expression of GFP.
Moynahan et al [24] have used such a GFP recombination
substrate to demonstrate that cells with defective BRCA2
protein are deficient in their ability to repair the I-SceI-
induced DSB through homologous recombination. Expres-
sion of I-SceI resulted in 1 out of 1400 cells producing
GFP via homologous recombination in the human pancre-
atic tumor cell line CAPAN-1. CAPAN-1 cells carry a dele-
tion of BRCA2 on one homolog and codes for a protein
truncated at amino acid 1981 on the other homolog. The
authors indicate that the level of I-SceI-induced recombi-
nation in CAPAN-1 is over 100-fold less than that seen
using other (BRCA2+) human tumor cell lines. The differ-
ent lines examined, however, are very likely to differ geneti-
cally from CAPAN-1 cells not only at the BRCA2 locus,
but also at a very large number of additional loci. This
raises the possibility that some or even all of the recombi-
national repair defect seen in CAPAN-1 could be due to
mutations at non-BRCA2 loci.
While Moynahan et al were careful to point out this
problem, two sets of results argue against the possibility
that the recombinational repair deficiency of CAPAN-1
cells is completely independent of its defect in BRCA2.
First, in the same study [24], recombination in a mouse ES
cell line that expresses only truncated BRCA2 protein was
measured. This line was found to have lower recombina-
tion efficiency than isogenic cells expressing full-length
BRCA2 (the defect observed was about fivefold to
sixfold). Second, in an independent study, Powell was
able to compare derivatives of CAPAN-1 that differed only
in their ability to express full-length BRCA2 protein (S.
Powell, personal communication, 2001). In these experi-
ments, the derivative expressing full-length BRCA2
yielded 10-fold more recombinants than controls express-
ing only truncated BRCA2 (S. Powell, personal communi-
cation, 2001). While the experimental design of these
experiments was somewhat different from that of Moyna-
han et al [24], the results raise the possibility that CAPAN-
1 cells have more than one mutation that lowers the
Figure 1
Recombination substrates used for assaying homology-directed repair.
Cutting at the I-SceI site within the mutant GFP (SceGFP) results in a
double-strand break that can be repaired through homologous gene
conversion using a 3′-truncated copy of GFP as sequence donor. The
mechanism results in the formation of a functional copy of the GFP
gene. The model shown assumes gene conversion occurs via the
synthesis-dependent annealing mechanism.Breast Cancer Research    Vol 3 No 5 Orelli and Bishop
efficiency of recombinational repair relative to that
observed in other human cell lines. Conversely, the
BRCA2 defect in CAPAN-1 could be fully responsible for
the 100-fold defect in recombination if the level of BRCA2
complementation observed by Powell was incomplete.
Furthermore, the discrepancy between the 100-fold differ-
ence between CAPAN-1 and the other human lines as
compared with the fivefold to sixfold difference between
the Brca2lex1/lex2 cells and Brca2+/+ ES cells might simply
be accounted for by the fact that Brca2lex1/lex2 is not a null
allele. Additional studies are likely to shed light on the effi-
ciency of BRCA2-independent recombination pathways.
Taken together, the results indicate that BRCA2 is indeed
required for high levels of recombinational repair in both
human and mouse. 
The function of BRCA2–RAD51 interaction
The second paper providing evidence, by Davies et al [26],
is a biochemical study of the interaction between the homol-
ogous recombinase RAD51 and a peptide consisting of
one of the eight BRC repeats from human BRCA2. Expres-
sion of a single BRC repeat (BRC4) had previously been
reported to act as an inhibitor of DNA repair by Chen et al
[27]. These investigators showed that expression of con-
structs containing the BRC4 repeat in MCF-7 cells
enhances the radiosensitivity of cells and blocks both the
G2/M delay associated with damage and the ability of the
transfected cells to assembly subnuclear RAD51 foci. In the
paper by Davies et al, data provide evidence for a plausible
mechanism of the dominant negative effect associated with
expression of a single BRC repeat. DNA binding assays
and electron microscopy methods were used to show that a
BRC3 peptide interferes with the ability of RAD51 to
assemble into oligomeric filaments on DNA. A BRC4
peptide was also reported to inhibit the RAD51–DNA inter-
action. These experiments raise the possibility that the full-
length BRCA2 protein could act as a negative regulator of
inappropriate RAD51–DNA interaction. 
The final experiment reported by Davies et al [26] is
particularly important with respect to understanding the
mechanism(s) through which BRCA2 promotes RAD51-
dependent recombination. The localization of RAD51 was
examined in CAPAN-1 cells, the same human tumor line
examined by Moynahan et al [24]. It had been shown pre-
viously that the small amount of truncated BRCA2 protein
expressed by CAPAN-1 cells was mislocalized to the cyto-
plasm, consistent with the fact that the truncation protein
lacks a nuclear localization signal [28]. Davies et al
showed CAPAN-1 cells to be defective in nuclear localiza-
tion of RAD51, raising the possibility that RAD51 is nor-
mally carried to the nucleus by binding BRCA2. It is
possible that RAD51 may alternatively be capable of
BRCA2-independent transport, but mislocalization of
BRCA2 to the cytoplasm may sequester RAD51 and
block its normal mode of transport. Support for the
hypothesis that the observed mislocalization of RAD51 is
an indirect consequence of the BRCA2 defect requires
reintroduction of functional BRCA2 into CAPAN-1. 
Given the elaborate nature of the RAD51–BRCA2 interac-
tion, it seems somewhat unlikely that the only role of
BRCA2 in promoting recombination is to serve as a spe-
cific nuclear transporter of RAD51. An attractive alterna-
tive, favored by Davies et al [26], is that the association of
RAD51–BRCA2 is required to maintain RAD51 in a form
that is in a state of ‘readiness’ (Fig. 2a). In the absence of
this interaction with BRCA2, RAD51 might exist in a form
that is not capable of being recruited into a functional
repair complex when damage occurs. For example, previ-
ous studies indicated that RAD51 shows little binding
preference for single-strand DNA (ssDNA) over double-
Figure 2
Potential roles of BRCA2 in promoting assembly of Rad51 at sites of
DNA damage. Chromosomal DNA is shown as pairs of straight lines,
Rad51 as open circles, and BRCA2 as grey bars. (a) Prevention of
nonproductive DNA interactions. BRCA2–Rad51 interaction is
proposed to suppress Rad51–DNA interactions until DNA damage is
present. When damage occurs, Rad51 is recruited to damaged sites
where is polymerizes into nucleoprotein filaments. In this model,
BRCA2 is not required for assembly of functional complexes at
damaged sites, only to prevent a substantial fraction of Rad51 from
being sequestered in a nonfunctional form. In a BRCA2-defective cell,
mutant Rad51 becomes associated with DNA at random sites and is
therefore not readily recruited to sites of damage. (b) Positive
regulation. BRCA2 is proposed to be required for Rad51 to assemble
into functional recombinational repair complexes at sites of damage. In
BRCA-defective cells, Rad51 fails to associate with sites of damage
due to lack of an assembly factor.strand DNA (dsDNA) [3,29]. This result could mean that
regulatory factors, such as BRCA2, are required to sup-
press RAD51–dsDNA interactions to prevent sequestration
of RAD51 in a nonfunctional form. Alternatively, or in addi-
tion, suppression of RAD51–ssDNA interaction might be
important for preventing RAD51 from binding to the regions
of ssDNA that form during normal DNA replication. BRCA2
may thus promote RAD51 assembly into recombinational
repair complexes via a negative regulatory mechanism (i.e.
by blocking RAD51–DNA interaction until damage has
occurred and factors required for ‘productive’ assembly of
RAD51 at damaged sites are in place). As mentioned previ-
ously, the ability of a BRC peptide to repress the
RAD51–DNA interaction could reflect a role of full-length
protein in suppressing unwanted RAD51–DNA interactions.
Yet another potential role for BRCA2 in promoting
RAD51-dependent recombinational repair is a positive
role in assembly of RAD51 at damaged sites (Fig. 2b).
Several proteins that interact with RAD51 are thought to
‘mediate’ assembly of RAD51 at sites of DNA damage
(reviewed in [30]). RAD51 paralogs in particular, including
XRCC2, XRCC3, RAD51B, RAD51C and RAD51D, may
function as a complex that actively promotes RAD51
assembly [31]. BRCA2 could cooperate with RAD51 par-
alogs in promoting RAD51 assembly, or even provide an
alternative assembly pathway. The observation that
BRCA2 localizes to damage-induced subnuclear foci with
RAD51 seems consistent with the possibility that BRCA2
plays a positive role in assembly of the recombination
complex [11].
Finally, it is important to note that the two models for the
function of the BRCA2–RAD51 interaction shown in
Figure 2 are not mutually exclusive. BRCA2 could prevent
inappropriate RAD51 assembly in the absence of damage
and promote functional RAD51 assembly at DNA lesions
during the damage response. Further experiments are
clearly required to clarify the functional interactions
between BRCA2 and RAD51 during recombinational
repair. It should be relatively straightforward to determine
whether the role of BRCA2 is limited to transporting
RAD51 to the nucleus. If this were the case, addition of a
nuclear localization signal to RAD51 should suppress the
RAD51-mediated phenotypes associated with a BRCA2
mutation. However, biochemical experiments are needed
to determine whether full-length BRCA2 blocks or pro-
motes RAD51–DNA interaction. Such experiments could
also reveal additional roles for BRCA2 in recombinational
repair. However, several technical obstacles, including the
large size of BRCA2, promise to make biochemical
characterization of BRCA2 function difficult.
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